| |
Learn how you can access the IQVIA Brand Analytics Platform — a self-service, intuitive technology that offers demonstrated, provable results for accurate, reliable, and repeatable answers to your most important business questions. Watch the video now!
|
|
|
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk, and addressing the specific drug supply challenges commonly associated with complex trial designs. Register now.
|
|
| By Max Bayer More companies laid off staff last month than in January 2022, driven by trims at billion-dollar Big Pharmas and smaller biotechs that had to downsize for the second time in less than a year. |
|
|
|
By Angus Liu In an unusual move, the FDA requested an expanded approval of breast cancer drug Ibrance from Pfizer. And the New York pharma won the go-ahead without additional clinical efficacy data. |
By James Waldron,Annalee Armstrong,Nick Paul Taylor After a slow 2022, will we see a return to form for biopharma M&A? And, if so, which biotechs does Big Pharma have in its sight? Here are our predictions. |
By Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Angus Liu,Zoey Becker Heading into 2022, top drugmakers had $1.7 trillion in dealmaking firepower, fueling expectations among analysts that the industry was due for a gangbusters M&A year. Well, that didn’t quite pan out. |
|
Wednesday, February 15, 2023 | 1pm ET / 10am PT Biosimilars continue to gain global acceptance and momentum, with 2023 set to be a landmark year. However, the complex and ever-changing regulatory environment is still a challenge. Join industry experts for an important discussion on biosimilar regulatory trends and key insights for navigating the biosimilar regulatory landscape. Register now.
|
|
By Max Bayer Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is closing its doors after seven years. Federal records show that both of the company's ongoing clinical trials have wrapped up. |
By Kevin Dunleavy Despite a plan to significantly jack up the price of Comirnaty when the U.S. goes to a commercial model this year for COVID-19 vaccines, Pfizer expects revenue from the shot to plummet by 64% in 2023. And COVID oral antiviral Paxlvoid will be in no better situation, Pfizer said Tuesday. |
By Conor Hale Researchers at King’s College London have found that a blood test can help predict a person’s risks of Alzheimer’s disease years before a clinical diagnosis, by evaluating the body’s ability to form new brain cells. |
By Fraiser Kansteiner Amgen is cutting around 300 jobs in the U.S.—mainly along commercial lines—a company spokesperson said in an email confirming “recently announced organizational changes.” |
By Gabrielle Masson In the pandemic's third year, Pfizer could do whatever it wanted thanks to billions reaped from the COVID-19 shot Comirnaty and antiviral Paxlovid. Instead, executives are signaling a somewhat restrained approach, cutting rare disease assets, seeking external partnerships and bumping up the R&D budget by 8.7% for 2023. |
By Angus Liu Merck & Co.’s Keytruda won the FDA’s permission to enter early-stage disease with an approval that trumps Roche’s Tecentriq. But there are two small caveats. |
By Helen Floersh Scientists found that melanoma cells can grow or shrink in response to therapy, paving the way for treatments that target them based on size. |
By Fraiser Kansteiner Citing the evolution of India's healthcare scene during the COVID-19 pandemic, a spokesperson for Sanofi in India told Fierce Pharma that “some activities” at its Medchal and Muppireddypally sites near the city of Hyderabad “are no longer viable.” As a result, Sanofi is offering a voluntary retirement scheme to all staffers at the production facilities. The move could affect some 800 staffers, Reuters reports. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss what we can expect from the obesity market in 2023. We also recap the drugs approved last year. |
|
|---|
|
|
|
Thursday, Feb 16, 2023 | 2:00pm ET During this session, NetApp will explore how data is leveraged in Life Sciences to create a data fabric strategy that’s aligned to your business. This includes how to detailing each cycle of the data foundation for data governance and quality, data accessibility, data platforms, data as a service, data as a business, predictive intelligence, optimizing how solutions are managed across the data lifecycle, and more. Register now.
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| WhitepaperAccelerating bioproduction towards high performance and scale Sponsored by: Capgemini Americas Inc. |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
